

1 **ddPCR: a more sensitive and accurate tool for SARS-CoV-2**  
2 **detection in low viral load specimens**

3 Tao Suo<sup>1,†</sup>, Xinjin Liu<sup>2,†</sup>, Ming Guo<sup>2,†</sup>, Jiangpeng Feng<sup>2,†</sup>, Wenjia Hu<sup>3,†</sup>, Yang Yang<sup>2</sup>,  
4 Qiuhan Zhang<sup>2</sup>, Xin Wang<sup>2</sup>, Muhanmmad Sajid<sup>2</sup>, Dong Guo<sup>2</sup>, Zhixiang Huang<sup>2</sup>,  
5 Liping Deng<sup>3</sup>, Tielong Chen<sup>3</sup>, Fang Liu<sup>2</sup>, Xu Ke<sup>2</sup>, Yuan Liu<sup>2</sup>, Qi Zhang<sup>2</sup>, Yingle Liu<sup>2</sup>,  
6 Yong Xiong<sup>3,\*</sup>, Guozhong Chen<sup>1,\*</sup>, Yu Chen<sup>2,\*</sup>, Ke Lan<sup>2,\*</sup>

7

8 Affiliations

9 <sup>1</sup>State Key Laboratory of Virology, Renmin Hospital, Wuhan University, Wuhan, P. R.  
10 China

11 <sup>2</sup>State Key Laboratory of Virology, Modern Virology Research Center, College of Life  
12 Sciences, Wuhan University, Wuhan, P. R. China.

13 <sup>3</sup>Department of Infectious Disease, Zhongnan Hospital, Wuhan University, Wuhan, P.  
14 R. China

15

16 <sup>†</sup>These authors contributed equally

17

18 \*Correspondence authors: Ke Lan, State Key Laboratory of Virology, Modern  
19 Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, P. R.  
20 China. E-mail: klan@whu.edu.cn, Yu Chen, State Key Laboratory of Virology,  
21 Modern Virology Research Center, College of Life Sciences, Wuhan University,  
22 Wuhan, P. R. China. E-mail: chenyu@whu.edu.cn, Guozhong Chen, State Key  
23 Laboratory of Virology, Renmin Hospital, Wuhan University, Wuhan, P. R. China.  
24 E-mail: guozhongch6389@163.com, Yong Xiong, Department of Infectious  
25 Disease, Zhongnan Hospital, Wuhan University, Wuhan, P. R. China. E-mail:  
26 yongxiong64@163.com.

27

28 Word count (abstract): 246

29

30 Word count (main text): 2114

31

32 **Abstract**

33 **Background:** Real-Time PCR (RT-PCR) is widely used as the gold standard for  
34 clinical detection of SARS-CoV-2. However, due to the low viral load in patient  
35 throat and the limitation of RT-PCR, significant numbers of false negative reports are  
36 inevitable, which should not be ignored.

37 **Methods:** We explored the feasibility of droplet digital PCR (ddPCR) to detect  
38 SARS-CoV-2 from 57 clinical pharyngeal swab samples and compared with RT-PCR  
39 in terms of the sensitivity and accuracy. Among 57 samples, all of which were  
40 reported as negative nucleic acid by officially approved clinical RT-PCR detection, 43  
41 samples were collected from suspected patients with fever in clinic, and 14 were from  
42 supposed convalescents who were about to discharge after treatment. The experiment  
43 was double-blind.

44 **Results:** The lower limit of detection of the optimized ddPCR is at least 500 times  
45 lower than that of RT-PCR. The overall accuracy of ddPCR for clinical detection is  
46 94.3 %. 33 out of 35 negative pharyngeal swab samples checked by RT-PCR were  
47 correctly judged by ddPCR based on the follow-up investigation. In addition, 9 out of  
48 14 (64.2 %) supposed convalescents with negative nucleic acid test twice by RT-PCR  
49 were positive by ddPCR detection.

50 **Conclusions:** ddPCR shows superiority for clinical detection of SARS-CoV-2 to  
51 reduce the false negatives, which could be a powerful complement to the current  
52 standard RT-PCR. Before the ddPCR to be approved for diagnosis, the current clinical  
53 practice that the convalescent continues to be quarantined for 2 weeks is reasonable  
54 and necessary.

55

56 Key words: SARS-CoV-2; droplet digital PCR; RT-PCR; clinical detection

57

58 **Introduction**

59 The recent outbreak of coronavirus disease 2019 (COVID-19) caused by the infection  
60 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a great  
61 threat to public health all over the world.<sup>1,2</sup> On February 28, 2020, the world health  
62 organization (WHO) has upgraded the global risk level of this viral pneumonia from  
63 "high" to "very high". According to WHO and Chinese Center for Disease Control  
64 and Prevention (CDC), the current gold standard for the diagnosis of SARS-CoV-2  
65 infection is based on the real-time fluorescent quantitative PCR (RT-PCR), which  
66 means that the nucleic acid of SARS-CoV-2 could be detected in patient specimens  
67 using RT-PCR.<sup>3,4</sup> However, the disadvantages of insufficient detection of RT-PCR are  
68 more and more prominent, especially the problem of detection dynamic range in the  
69 clinical application. At present, it has been found in clinical practice that some  
70 patients had fever, and chest CT showed symptoms of suspected viral pneumonia such  
71 as lower lobe lesions of the lungs, but the nucleic acid test of pharyngeal swab did not  
72 show positive results until 5-6 days after the onset of viral pneumonia. It was  
73 estimated that only 30 %-60 % positive results can be obtained among COVID-19  
74 patients that further confirmed by chest CT.<sup>5</sup> This might be explained by the relatively  
75 low viral load in the throat of patients and the sensitivity limitation of RT-PCR  
76 technology, which inevitably produced the false negatives during the clinical  
77 diagnosis, leading to a potential risk of viral transmission. Besides, supposed  
78 convalescent, who is about to discharge, also need multiple tests with negative results  
79 for confirmation. Therefore, it is a pressing needs for a more sensitive and accurate  
80 detection method for the pathogenic detection.

81

82 Digital PCR is based on the principles of limited dilution, end-point PCR, and Poisson  
83 statistics, with absolute quantification as its heart.<sup>6</sup> It has broader dynamic range  
84 without external interference and robustness to variations in PCR efficiency.<sup>7-9</sup> In  
85 2011, Hindson developed the droplet digital PCR (ddPCR) technology based on  
86 traditional digital PCR.<sup>10</sup> The reaction mixture can be divided into tens of thousands  
87 of nanodroplets during the process. These vast and highly consistent oil droplets

88 substantially improve the detection dynamic range and accuracy of digital PCR in a  
89 low-cost and practical format.<sup>11</sup> In recent years, this technology has been widely used,  
90 such as analysis of absolute viral load from clinical samples, analysis of gene copy  
91 number variation, rare allele detection, gene expression, microRNA analysis and  
92 genome edit detection *et al.*<sup>12,13,14,15</sup> Here, taking the advantages of ddPCR, we  
93 optimized the preparation of pharyngeal swab samples, and develop a workflow of  
94 ddPCR to detect SARS-CoV-2 using Chinese CDC approved primer and probe sets.  
95 Based on the results of this optimized ddPCR system, we showed that the overall  
96 accuracy of the ddPCR for clinical pathogen detection is 94.3 %, and 64.2 % of  
97 supposed convalescents with two consecutive negative nucleic acid tests by RT-PCR  
98 still carry SARS-CoV-2.

99

## 100 **Materials and methods**

101

### 102 **Ethics statement**

103 This study was approved by the Ethics Committee of the Renmin Hospital and  
104 Zhongnan Hospital of Wuhan University. The analysis was performed on existing  
105 samples collected during standard diagnostic tests, posing no extra burden to patients,  
106 as described previously.<sup>2</sup>

107

### 108 **Specimen collection and RNA extraction**

109 Pharyngeal swab samples were obtained from clinical suspected patients with fever or  
110 rehabilitation quasi-discharged patients of COVID-19 at Renmin Hospital and  
111 Zhongnan Hospital of Wuhan University according to the interim guidance of WHO.  
112 Pharyngeal swabs were soaked in 500 µl PBS and vortexed with diameter of 3 mm  
113 beads (Novastar, China) for 15 seconds immediately. Total RNA was extracted from  
114 the supernatant using QIAamp viral RNA mini kit (Qiagen) following manufacturer's  
115 instruction. First strand cDNA was synthesized using PrimeScript RT Master Mix  
116 (TakaRa) with random primer and oligo dT primer.

117

118 **Primers and probes**

119 The primers and probes targeted the ORF1ab and N of SARS-CoV-2 according to  
120 Chinese CDC. Target 1 (ORF1ab), forward: 5'-CCCTGTGGGTTTTACACTTAA-3',  
121 reverse: 5'-ACGATTGTGCATCAGCTGA-3', probe:  
122 5'-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3';  
123 Target 2 (N), forward: 5'-GGGGAACCTTCTCCTGCTAGAAT-3',  
124 reverse: 5'-CAGACATTTTGCTCTCAAGCTG-3',  
125 probe: 5'-FAM-TTGCTGCTGCTTGACAGATT-TAMRA-3'.<sup>16</sup>

126

127 **Droplet Digital PCR workflow**

128 All the procedure follow the manufacture instructions of the QX200 Droplet Digital  
129 PCR System using supermix for probe (no dUTP) (Bio-Rad). Briefly, the TaqMan  
130 PCR reaction mixture was assembled from a 2× supermix for probe (no dUTP)  
131 (Bio-Rad), 20× primer and probes (final concentrations of 900 and 250 nM,  
132 respectively) and template (variable volume) in a final volume of 20 µl. Twenty  
133 microliters of each reaction mix was converted to droplets with the QX200 droplet  
134 generator (Bio-Rad). Droplet-partitioned samples were then transferred to a 96-well  
135 plate, sealed and cycled in a T100 Thermal Cycler (Bio-Rad) under the following  
136 cycling protocol: 95 °C for 10 min (DNA polymerase activation), followed by 40  
137 cycles of 94 °C for 30 s (denaturation) and 60 °C for 1 min (annealing) followed by an  
138 infinite 4-degree hold. The cycled plate was then transferred and read in the FAM  
139 channels using the QX200 reader (Bio-Rad).

140

141 **RT-PCR**

142 The primers and probes used in ddPCR are also used in RT-PCR. A 30-µl reaction was  
143 set up containing 10 µl of RNA, 18.5 µl of reaction buffer provided with the one step  
144 RT-PCR system and 1.5 µl enzyme mix (BGI BIOTECHNOLOGY). Thermal cycling  
145 was performed at 50 °C for 20 min for reverse transcription, followed by 95°C for 10  
146 min and then 40 cycles of 95 °C for 15 s, 60 °C for 30 s in BIO-RAD CFX96 Touch  
147 RT-PCR system.

148

#### 149 **Data statistical analysis**

150 Analysis of the ddPCR data was performed with Quanta Soft analysis software  
151 v.1.7.4.0917 (Bio-Rad) that accompanied the droplet reader calculate the  
152 concentration of the target DNA sequences, along with their Poisson-based 95 %  
153 confidence intervals. The positive populations for each primer/probe are identified  
154 using positive and negative controls with single (i.e., not multiplexed) primer–probe  
155 sets. The concentration reported by QuantaSoft equals copies of template per  
156 microliter of the final 1× ddPCR reaction, which was also used in all the results. In  
157 addition, plots of linear regression were conducted with GraphPad Prism 7.00, and  
158 probit analysis for lower limit of detection (LLoD) was conducted with StatsDirect  
159 software v3.2.9. Lower limit of quantitation (LLoQ) and LLoD were defined as the  
160 lowest concentration at which 95 % and 50 % of positive samples were detected,  
161 respectively.

162

#### 163 **Results**

##### 164 **Comparison of the lower limit between ddPCR and the standard RT-PCR**

165 Using a manual threshold to define positivity, 9 % of negative controls (3/32) were  
166 scored as positive due to one single positive droplet (data not shown). The presence of  
167 two positive droplets or more was not observed for negative controls. Serial dilutions  
168 of a positive control DNA fragment of SARS-CoV-2 were tested with primers/probe  
169 sets targeting ORF1ab and N of SARS-CoV-2, respectively for ddPCR. It shows good  
170 linearity ( $R^2$ : 0.9932 and 0.9824, respectively) (Fig. 1A and 1B). Reportable range of  
171 ddPCR is from 10 copies/ $\mu$ l to 2500 copies/ $\mu$ l for both ORF1ab and N primes/probe  
172 sets. In contrast, the dynamic range of RT-PCR is from 50 copies/ $\mu$ l to  $10^5$  copies/ $\mu$ l  
173 for both ORF1ab and N primes/probe sets (Fig. 1C and 1D). To define the limit of  
174 quantification of ddPCR, five low concentrations of plasmid control were analyzed  
175 with 8 replicates. The lower limit of quantitation (LLoQ) of the optimized ddPCR is  
176 1.003 copies/ $\mu$ l and 0.415 copies/ $\mu$ l for ORF1ab and N primers/probe sets,  
177 respectively. The lower limit of detection (LLoD) of the optimized ddPCR is 0.109

178 copies/ $\mu$ l and 0.021 copies/ $\mu$ l for ORF1ab and N primers/probe sets, respectively (Fig.  
179 2), which is at least 500 times lower than the RT-PCR detection kit used in current  
180 clinical test. Therefore, the ddPCR is more sensitive for samples with low level  
181 analyte.

182

### 183 **Detection of SARS-CoV-2 from patient specimens with ddPCR**

184 57 clinical pharyngeal swab samples (Fig. 3), which were judged to be negative by  
185 both officially approved clinical RT-PCR detection and the commercial RT-PCR  
186 detection kit for double check (generally referred to as RT-PCR), were tested with  
187 ddPCR in double-blind. We did not know any information, results of clinical  
188 diagnosis and status of enrolled patients during the tests. The follow-up investigation  
189 revealed those information after ddPCR tests. Compared with the information and  
190 clinical diagnosis, our results show that the overall accuracy of the optimized ddPCR  
191 is 94.3 % and 64.2 % of supposed convalescents are still carrying SARS-CoV-2.  
192 Details are as follows (Fig. 3) (Table 1 and 2):

193 Firstly, among 27 febrile suspected patients whose SARS-CoV-2 nucleic acid were  
194 negative initially tested by RT-PCR, 25 out of 27 were detected with ddPCR as  
195 positive and 2 out of 27 were negative. However, all 27 patients were diagnosed with  
196 SARS-CoV-2 infection by chest CT as well as RT-PCR in subsequent follow-up  
197 investigations, and all of them were hospitalized. As a result, 92.6 % of patients with  
198 false negative nucleic acid test could be identified as positive by the optimized ddPCR  
199 (Table 1).

200 Secondly, pharyngeal swabs of 8 febrile patients with negative results tested by  
201 RT-PCR were also tested negative by ddPCR. In the follow-up investigation  
202 COVID-19 was excluded based on the normal results of chest CT and RT-PCR (Table  
203 1).

204 Thirdly, pharyngeal swabs collected from 8 febrile suspected patients in the clinic  
205 recently with negative nucleic acid tests by RT-PCR, were detected positive by  
206 ddPCR. However, chest CT of these 8 patients did not show any abnormalities upon  
207 their first visit the clinic. According to official clinical guidelines, these 8 patients



208 were home quarantined and no further followed-up by us (Table 1).  
209 Finally, pharyngeal swabs of 14 supposed convalescent were tested negative in two  
210 consecutive tests by RT-PCR (Table 2). However, using ddPCR, 9 out of 14 were  
211 positive with a positive rate of 64.2 %. Therefore, the current clinical practice that the  
212 convalescent continues to be quarantined for 2 weeks is reasonable and necessary.  
213 In conclusion, compared with RT-PCR, ddPCR show superiority for clinical detection  
214 of SARS-CoV-2 to reduce the false negatives, which could be a powerful complement  
215 to the current standard RT-PCR.

216

## 217 **Discussion**

218 More and more nucleic acid detection kits have been developed for SARS-CoV-2  
219 recently based on RT-PCR to meet the requirement of large-scale clinical molecular  
220 diagnosis. It has been reported that 6 kinds of RT-PCR detection kits were compared  
221 and analyzed for their detection performance. Results showed that there are  
222 differences in the detection ability of these kits for weakly positive samples, and the  
223 accuracy, sensitivity and reproducibility of some reagents are not ideal <sup>17</sup> In the  
224 meantime, many efforts have been focusing on developing better and complementary  
225 technology for clinical diagnosis of SARS-CoV-2, due to the limited sensitivity and  
226 precision of RT-PCR for viral quantitation. Different from RT-PCR that the data are  
227 measured from a single amplification curve and a Cq value, which is highly  
228 dependent on reaction efficiency, primer dimers and sample contaminants, ddPCR is  
229 measured at reaction end point which virtually eliminates these potential pitfalls.  
230 Results in this work proved that ddPCR is more sensitive (Fig. 1) and accurate for low  
231 viral load diagnosis (Fig. 2), which can greatly reduce the false negatives detection  
232 (Fig 3).  
233 Based on two primers/probe sets targeting ORF1ab and N of SARS-CoV-2, results  
234 showed that N primers/probe set was more sensitive compared to that of ORF1ab.  
235 Among 42 samples that were judged as positive with ddPCR, 40 in 42 were detected  
236 as positive by N primers/probe set, and 12 in 42 were detected as positive by ORF1ab  
237 primers/probe set. This could be explained by the subgenomic RNA discontinuous

238 replication and transcription model of coronavirus. The genome RNA of  
239 SARS-CoV-2 encodes single copy of ORF1ab and N, respectively. In contrast, a  
240 nested set of around 10 subgenomic RNAs (sgRNAs), each of which encodes one  
241 copy of N, are synthesized by viral replication and transcription complex in a manner  
242 of discontinuous transcription<sup>18,19,20</sup>. Therefore, the copy numbers of N gene is  
243 significantly higher than that of ORF1ab gene in SARS-CoV-2 infected cells.

244 Although 2 patients, who were clinically confirmed by chest CT and RT-PCR  
245 subsequently, were reported as negative nucleic acid in pharyngeal swabs by our  
246 ddPCR, leading to 2 false negative reports by ddPCR in 35 cases (5.7 % missing rate),  
247 the overall accuracy of SARS-CoV-2 detection is significantly improved, which will  
248 benefit to the early diagnosis, intervention and treatment.

249 Notably, 64.2 % supposed convalescent patients, who are negative for pharyngeal  
250 swab nucleic acid tests twice by RT-PCR, are still carrying SARS-CoV-2 based on our  
251 work. Although there is no evidence that such COVID-19 convalescent carrying  
252 SARS-CoV-2 will be infectious to other healthy person, the risk still exists. Therefore,  
253 the current clinical practice that the convalescent continues to be quarantined for 2  
254 weeks is reasonable and necessary. And we recommend that ddPCR could be a  
255 complement to the current standard RT-PCR to re-confirm the convalescent, which  
256 will benefit to reduce the risk of the SARS-CoV-2 epidemic and social panic.

257

#### 258 **Author Contributions**

259 YC, KL conceptualized the study design. TS, WH, LD, TC, YX, and GC recruited the  
260 patients, collected specimens, collected demographic, clinical data; XL, MG, QZ, XW,  
261 YY, MS, DG and ZH did the laboratory tests. JF, YL and QZ plotted the figures; XL,  
262 MG, JF and YC analyzed the data; ZH, XK, YL, YIL and YC interpreted the  
263 results; JF wrote the initial drafts of the manuscript; YC and KL revised the  
264 manuscript and FL and KX commented on it. All authors read and approved the final  
265 report.

266

#### 267 **Funding**

268 This study was supported by National Science and Technology Major Project  
269 (#2018ZX10733403 and #2018YFA0900801), China NSFC grants (#81672008) and  
270 Hubei Natural Science Foundation (#2018CFA035), Basic Scientific Research  
271 Foundation of Central Universities (#2042019gf0026), Ministry of Science and  
272 Technology of China, the National Mega Project on Major Infectious Disease  
273 Prevention (#2017ZX10103005) and National Key Research and Development  
274 Program of China (#2018YFE0204500). None of the funders had any role in the study  
275 design and the collection, analysis, and interpretation of data or in the writing of the  
276 article and the decision to submit it for publication. The researchers confirm their  
277 independence from funders and sponsors.

278

### 279 **Acknowledgement**

280 We are grateful to Taikang Insurance Group Co., Ltd and Beijing Taikang Yicai  
281 Foundation for their great support to this work.

282

### 283 **Declaration of interests**

284 No authors have received research funding from the company whose commercial  
285 products were used in this work. All authors report no competing interests. All authors  
286 have completed the Unified Competing Interest form.

287

### 288 **Reference**

- 289 1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human  
290 respiratory disease in China. *Nature* 2020;  
291 <https://doi.org/10.1038/s41586-020-2008-3>
- 292 2. Chen L, Liu W, Zhang Q, et al. RNA based mNGS approach identifies a novel  
293 human coronavirus from two individual pneumonia cases in 2019 Wuhan  
294 outbreak. *Emerg Microbes Infect* 2020;9(1):313–9.
- 295 3. World Health Organization. Laboratory testing for 2019 novel coronavirus  
296 (2019-nCoV) in suspected human cases. [Internet]. 2020; Available from:  
297 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-g>

- 298 guidance/laboratory-guidance
- 299 4. General Office of the National Health and Health Commission O of the SA of  
300 TCM. Diagnosis and treatment of pneumonitis with a new type of coronavirus  
301 infection (trial version 5) [Internet]. 2020;Available from:  
302 <http://bgs.satcm.gov.cn/zhengcewenjian/2020-02-06/12848.html>
- 303 5. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the  
304 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a  
305 Report of 72 314 Cases From the Chinese Center for Disease Control and  
306 Prevention. JAMA [Internet] 2020;2019:25–8. Available from:  
307 <http://www.ncbi.nlm.nih.gov/pubmed/32091533>
- 308 6. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A  
309 1999;96(16):9236–41.
- 310 7. Pohl G, Shih I-M. Principle and applications of digital PCR. Expert Rev Mol  
311 Diagn 2004;4(1):41–7.
- 312 8. Sanders R, Mason DJ, Foy CA, Huggett JF. Evaluation of Digital PCR for  
313 Absolute RNA Quantification. PLoS One 2013;8(9):e75296.
- 314 9. White RA, Blainey PC, Fan HC, Quake SR. Digital PCR provides sensitive  
315 and absolute calibration for high throughput sequencing. BMC Genomics  
316 2009;10(1):110–6.
- 317 10. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital  
318 PCR system for absolute quantitation of DNA copy number. Anal Chem  
319 2011;83(22):8604–10.
- 320 11. Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by  
321 droplet digital PCR versus analog real-time PCR. Nat Methods  
322 2013;10(10):1003–5.
- 323 12. Brunetto GS, Massoud R, Leibovitch EC, et al. Digital droplet PCR (ddPCR)  
324 for the precise quantification of human T-lymphotropic virus 1 proviral loads  
325 in peripheral blood and cerebrospinal fluid of HAM/TSP patients and  
326 identification of viral mutations. J Neurovirol 2014;20(4):341–51.
- 327 13. Caviglia GP, Abate ML, Tandoi F, et al. Quantitation of HBV cccDNA in

- 328 anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect  
329 occult infection. *J Hepatol* 2018;69(2):301–7. Available from:  
330 <https://doi.org/10.1016/j.jhep.2018.03.021>
- 331 14. Postel M, Roosen A, Laurent-Puig P, Taly V, Wang-Renault S-F.  
332 Droplet-based digital PCR and next generation sequencing for monitoring  
333 circulating tumor DNA: a cancer diagnostic perspective. *Expert Rev Mol*  
334 *Diagn* 2018;18(1):7–17.
- 335 15. Miyaoka Y, Mayerl SJ, Chan AH, Conklin BR. Detection and Quantification of  
336 HDR and NHEJ Induced by Genome Editing at Endogenous Gene Loci Using  
337 Droplet Digital PCR [Internet]. In: Karlin-Neumann G, Bizouarn F, editors.  
338 *Digital PCR: Methods and Protocols*. New York, NY: Springer New York;  
339 2018. p. 349–62. Available from:  
340 [https://doi.org/10.1007/978-1-4939-7778-9\\_20](https://doi.org/10.1007/978-1-4939-7778-9_20)
- 341 16. National Institute For viral Disease Control and prevention of PRC. Specific  
342 primers and probes for detection 2019 novel coronavirus [Internet]. 2020;  
343 Available from: [http://www.chinaivdc.cn/kyjz/202001/t20200121\\_211337.html](http://www.chinaivdc.cn/kyjz/202001/t20200121_211337.html)
- 344 17. Guo Y., Wang K., Zhang Y., Zhang W., Wang L. LP. Comparison and analysis  
345 of the detection performance of six new coronavirus nucleic acid detection  
346 reagents. *Chongqing Med* 2020;14(0):1671–8348.
- 347 18. Thiel V, Ivanov KA, Putics Á, et al. Mechanisms and enzymes involved in  
348 SARS coronavirus genome expression. *J Gen Virol* 2003;84(9):2305–15.
- 349 19. Hussain S, Pan J, Chen Y, et al. Identification of Novel Subgenomic RNAs and  
350 Noncanonical Transcription Initiation Signals of Severe Acute Respiratory  
351 Syndrome Coronavirus. *J Virol* 2005;79(9):5288–95.
- 352 20. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication,  
353 and pathogenesis. *J Med Virol* 2020;(January):1–6.
- 354  
355  
356  
357

358

359

360

361

362

363 **Figure legends**

364 **Figure 1.** Plot of results from a linearity experiment to determine reportable range of  
365 ddPCR and RT-PCR targeting for ORF1ab and N of SARS-CoV-2. (A and B)  
366 Expected values (converted to log<sub>10</sub>) were plotted on the X axis versus measured  
367 values (converted to log<sub>10</sub>) on the Y axis using Graph Pad Prism for ddPCR targeting  
368 ORF1ab and N. (C and D) Expected values (converted to log<sub>10</sub>) were plotted on the  
369 X axis versus measured Ct values on the Y axis using Graph Pad Prism for RT-PCR  
370 targeting ORF1ab and N. Data are representative of three independent experiments  
371 with 3 replicates for each concentration.

372

373 **Figure 2.** Probit analysis sigmoid curve reporting the lower limit of quantitation  
374 (LLoQ) and the lower limit of detection (LLoD) of ddPCR. Replicate reactions of  
375 SARS-CoV-2 (A) ORF1ab and (B) N were done at concentrations around the  
376 detection end point determined in preliminary dilution experiments. The X axis shows  
377 expected concentration (copies/μl). The Y axis shows fraction of positive results in all  
378 parallel reactions performed. The inner line is a probit curve (dose-response rule). The  
379 outer lines are 95 % CI. Data are representative of three independent experiments with  
380 8 replicates for each concentration.

381

382 **Figure 3.** Information diagram of detection results with ddPCR and subsequent  
383 clinical diagnosis for both convalescent and febrile suspected patients.

**Tables**

Table 1. Detection results of ddPCR for febrile and suspected patients of COVID-19.

Patient Number	Patient status	Result of official	Result of nucleic	Result of ddPCR		Judgment result of ddPCR	Result of chest CT	Disposition of Hospital
		nucleic acid test by	acid test by	(copies/ $\mu$ l)				
		RT-PCR	RT-PCR in lab	ORF1ab	N			
P1	Fever, suspected	Negative	Negative	0	0.1	Positive	Viral pneumonia	Hospitalized
P2	Fever, suspected	Negative	Negative	0	0.1	Positive	Viral pneumonia	Hospitalized
P3	Fever, suspected	Negative	Negative	0	0.1	Positive	Viral pneumonia	Hospitalized
P4	Fever, suspected	Negative	Negative	0	0.09	Positive	Viral pneumonia	Hospitalized
P5	Fever, suspected	Negative	Negative	0	0.07	Positive	Viral pneumonia	Hospitalized
P6	Fever, suspected	Negative	Negative	0	0.18	Positive	Viral pneumonia	Hospitalized
P7	Fever, suspected	Negative	Negative	0.15	0.68	Positive	Viral pneumonia	Hospitalized
P8	Fever, suspected	Negative	Negative	0.08	0.66	Positive	Viral pneumonia	Hospitalized



P9	Fever, suspected	Negative	Negative	0	0.08	Positive	Viral pneumonia	Hospitalized
P10	Fever, suspected	Negative	Negative	0	0.18	Positive	Viral pneumonia	Hospitalized
P11	Fever, suspected	Negative	Negative	0	0.23	Positive	Viral pneumonia	Hospitalized
P12	Fever, suspected	Negative	Negative	0.1	0.19	Positive	Viral pneumonia	Hospitalized
P13	Fever, suspected	Negative	Negative	0	0.18	Positive	Viral pneumonia	Hospitalized
P14	Fever, suspected	Negative	Negative	0	0.09	Positive	Viral pneumonia	Hospitalized
P15	Fever, suspected	Negative	Negative	0	0.37	Positive	Viral pneumonia	Hospitalized
P16	Fever, suspected	Negative	Negative	0	0.09	Positive	Viral pneumonia	Hospitalized
P17	Fever, suspected	Negative	Negative	0	0.16	Positive	Viral pneumonia	Hospitalized
P18	Fever, suspected	Negative	Negative	0.19	0.09	Positive	Viral pneumonia	Hospitalized
P19	Fever, suspected	Negative	Negative	0.1	0	Positive	Viral pneumonia	Hospitalized
P20	Fever, suspected	Negative	Negative	0	0.1	Positive	Viral pneumonia	Hospitalized
P21	Fever, suspected	Negative	Negative	0	0.33	Positive	Viral pneumonia	Hospitalized

P22	Fever, suspected	Negative	Negative	0.22	0.71	Positive	Viral pneumonia	Hospitalized
P23	Fever, suspected	Negative	Negative	0	0.16	Positive	Viral pneumonia	Hospitalized
P24	Fever, suspected	Negative	Negative	0	0.09	Positive	Viral pneumonia	Hospitalized
P25	Fever, suspected	Negative	Negative	0	0.16	Positive	Viral pneumonia	Hospitalized
P26	Fever, suspected	Negative	Negative	0	0	Negative	Viral pneumonia	Hospitalized
P27	Fever, suspected	Negative	Negative	0	0	Negative	Viral pneumonia	Hospitalized
P28	Fever, suspected	Negative	Negative	0	0.17	Positive	Normal	Home Quarantine
P29	Fever, suspected	Negative	Negative	0	0.06	Positive	Normal	Home Quarantine
P30	Fever, suspected	Negative	Negative	0	0.06	Positive	Normal	Home Quarantine
P31	Fever, suspected	Negative	Negative	0.08	0.2	Positive	Normal	Home Quarantine
P32	Fever, suspected	Negative	Negative	0	0.19	Positive	Normal	Home Quarantine
P33	Fever, suspected	Negative	Negative	0	0.27	Positive	Normal	Home Quarantine





P34	Fever, suspected	Negative	Negative	0.15	0.8	Positive	Normal	Home Quarantine
P35	Fever, suspected	Negative	Negative	0	0.1	Positive	Normal	Home Quarantine
P36	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P37	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P38	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P39	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P40	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P41	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P42	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded
P43	Fever, suspected	Negative	Negative	0	0	Negative	Normal	Excluded



Table 2. Detection results of ddPCR for supposed convalescent patients who is about to be discharged after treatment.

Patient Number	Patient status	Result of official		Result of ddPCR		Judgment result of ddPCR (Positive/Negative)
		nucleic acid test by	Result of nucleic	(copies/ $\mu$ l)		
		real time PCR (Positive/Negative)	acid test by RT-PCR in our lab	ORF1ab	N	
P44	Supposed convalescent	Negative	Negative	0	0.12	Positive
P45	Supposed convalescent	Negative	Negative	0	0.11	Positive
P46	Supposed convalescent	Negative	Negative	0.57	0.6	Positive
P47	Supposed convalescent	Negative	Negative	0	0.45	Positive
P48	Supposed convalescent	Negative	Negative	0	0.8	Positive
P49	Supposed convalescent	Negative	Negative	0.09	0	Positive
P50	Supposed convalescent	Negative	Negative	0	0.11	Positive
P51	Supposed convalescent	Negative	Negative	0.19	5.3	Positive
P52	Supposed convalescent	Negative	Negative	0.07	0.07	Positive

P53	Supposed convalescent	Negative	Negative	0	0	Negative
P54	Supposed convalescent	Negative	Negative	0	0	Negative
P55	Supposed convalescent	Negative	Negative	0	0	Negative
P56	Supposed convalescent	Negative	Negative	0	0	Negative
P57	Supposed convalescent	Negative	Negative	0	0	Negative

---





RT-PCR

57 cases  
Pharyngeal swab negative  
by RT-PCR

14 cases  
Convalescent

43 cases  
Fever, suspected

ddPCR

9 cases  
Pharyngeal swab  
positive by ddPCR

5 cases  
Pharyngeal swab  
negative by ddPCR

33 cases  
Pharyngeal swab  
positive by ddPCR

10 cases  
Pharyngeal swab  
negative by ddPCR

Chest CT

CT  
Pneumonia  
absorbed

CT  
Pneumonia  
absorbed

8 cases  
CT Normal

25+2 cases  
Viral pneumonia  
by Chest CT

8 cases  
CT Normal

Quarantine  
for 2 weeks

Quarantine  
for 2 weeks

Home  
quarantine

Hospitalized

Excluded